Access cutting-edge sjogren's disease treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access sjogren's disease specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related sjogren's disease treatment provided free
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Check if you qualify for this sjogren's disease clinical trial in Birmingham, AL
If you're searching for sjogren's disease treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sjogren's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.